Economic implications of cardiovascular disease management programs: moving beyond one-off experiments
Date
2015
Authors
Maru, S.
Byrnes, J.
Carrington, M.
Stewart, S.
Scuffham, P.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Expert Review of Pharmacoeconomics and Outcomes Research, 2015; 15(4):657-666
Statement of Responsibility
Shoko Maru, Joshua Byrnes, Melinda J Carrington, Simon Stewart and Paul A Scuffham
Conference Name
Abstract
Substantial variation in economic analyses of cardiovascular disease management programs hinders not only the proper assessment of cost-effectiveness but also the identification of heterogeneity of interest such as patient characteristics. The authors discuss the impact of reporting and methodological variation on the cost-effectiveness of cardiovascular disease management programs by introducing issues that could lead to different policy or clinical decisions, followed by the challenges associated with net intervention effects and generalizability. The authors conclude with practical suggestions to mitigate the identified issues. Improved transparency through standardized reporting practice is the first step to advance beyond one-off experiments (limited applicability outside the study itself). Transparent reporting is a prerequisite for rigorous cost-effectiveness analyses that provide unambiguous implications for practice: what type of program works for whom and how.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2015 Informa UK Ltd